Late and Reversible Kidney-Lung Failure after Intra-Bladder BCG Therapy

Olivier Mat, Rim Kada, Patrick Philippart, Quentin Mat, Steffy Larroze, Myriam Remmelink, Selda Aydin, Vincent Colombie

Department of Infectious Diseases of EpiCURA, Ath, Belgium.
Department of Lung Pathology, Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Department of Nephrology of EpiCURA, Ath, Belgium.
Department of Renal Pathology, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium.
Department of Surgery of EpiCURA, Ath, Belgium.

DOI: 10.4236/ojneph.2013.33022                

Abstract

We observed a 76-year-old man who presented “acute kidney-lung failure” 9 months after intravesical Bacillus Calmette-Guérin (BCG) adjuvant treatment for a T1 bladder cancer. He had inflammatory infiltration on chest radiography and required dialysis for acute renal failure. A percutaneous renal biopsy was performed and revealed tubulointerstitial nephritis with a moderate eosinophilic infiltrate without granulomatous lesion. After a few days, an open lung biopsy was also done due to respiratory deterioration. The anatomopathologic specimen demonstrated moderate fibrosis with lympho-neutrophilic infiltration and few aspecific granulomatous lesions without caseous necrosis. Sarcoidosis was suspected and high dose oral methylprednisolone was started. Three weeks later, Mycobacterium bovis was identified by Polymerase Chain Reaction on open lung biopsy. He responded well to steroids and tuberculostatic tri-therapy. After one month of immunosuppressive treatment, renal function was resolved and hemodialysis could be discontinued. Despite the frequent use of adjuvant BCG immunotherapy, systemic complications such as hepatitis, pneumonitis, spondylodiscitis or multiorgan failure are rare (<1%). Hematogenous dissemination which occurs a few weeks after traumatic instillations is usually suspected but not demonstrated because of absence of mycobacterium in histological specimen. Our case differs from those previously reported by the simultaneous presence of acid-fast bacilli highlighted on lung samples. We discuss the pathophysiology of BCG complications, the use of prophylactic or therapeutic treatment and recommend guidelines to prevent such complications.

Keywords

Corticosteroids; Hemodialysis; Intravesical BCG; Mycobacterium bovis; Pulmonary Granulomatosis; Renal Failure; Tubulointerstitial Nephritis; Urothelial Carcinoma

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	A. N. Alexandroff, A. M. Jackson, M. A. O’Donnell and K. James, “BCG Immunotherapy of Bladder Cancer: 20 Years on,” Lancet, Vol. 353, No. 9165, 1999, pp. 1689-1694. doi:10.1016/S0140-6736(98)07422-4
[2]	M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Bohle, J. Palou-Redorta and M. Rouprêt, “EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update,” European Urology, Vol. 59, No. 6, 2011, pp. 997-1008. doi:10.1016/j.eururo.2011.03.017
[3]	B. B. Houghton, V. Chalasani, D. Hayne, P. Grimison, C. S. Brown, M. I. Patel, I. D. Davis and M. R. Stockler, “Intravesical Chemotherapy Plus Bacilli Calmette-Guérin in Non-Muscle Invasive Bladder Cancer: A Systematic Review with Meta-Analysis,” BJU International, Vol. 111, No. 6, 2013, pp. 977-983. doi:10.1111/j.1464-410X.2012.11390.x
[4]	T. P. Kresowik and T. S. Griffith, “Bacillus Calmette-Guerin Immunotherapy for Urothelial Carcinoma of the Bladder,” Immunotherapy, Vol. 1, No. 2, 2009, pp. 281-288. doi:10.2217/1750743X.1.2.281
[5]	D. L. Lamm, “Complications of Bacillus Calmette-Guérin Immunotherapy,” Urologic Clinics of North America, Vol. 19, No. 3, 1992, pp. 565-572
[6]	M. J. Manzanera Escribano, E. Morales Ruiz, M. Odriozola Grijalba, E. Gutierrez Martínez, A. Rodriguez Antolín and M. Praga Terente, “Acute Renal Failure Due to Interstitial Nephritis after Intravesical Instillation of BCG,” Clinical and Experimental Nephrology, Vol. 11, No. 3, 2007, pp. 238-240. doi:10.1007/s10157-007-0483-6
[7]	S. E. Kennedy, S. Shrikanth and J. A. Charlesworth, “Acute Granulomatous Tubulointerstitial Nephritis Caused by BCG,” Nephrology Dialysis Transplantation, Vol. 21, No. 5, 2006, pp. 1427-1429. doi:10.1093/ndt/gfk071
[8]	C. G. Valentini, V. Bozzoli, A. R. Larici, L. M. Larocca, G. Delogu, G. Leone and L. Pagano, “Systemic Granulomatous Reaction Secondary to Treatment of Bladder Cancer with Bacillus Calmette-Guerin,” Mediterranean Journal of Hematology and Infectious Diseases, Vol. 4, No. 1, 2012, e2012040. doi:10.4084/mjhid.2012.040
[9]	J. D. Colmerano, R. Sanjuan-Jimenez, B. Ramos and P. Morata, “Miliary Pulmonary Tuberculosis Following Intravesical BCG Therapy: Case Report and Literature Review,” Diagnostic Microbiology and Infectious Disease, Vol. 74, No. 1, 2012, pp. 70-72. doi:10.1016/j.diagmicrobio.2012.05.026
[10]	O. Y. Gonzalez, D. M. Musher, I. Brar, S. Furgeson, M. R. Boktour, E. J. Septimus, R. J. Hamill and E. A. Graviss, “Spectrum of Bacille Calmette-Guérin (BCG) Infection after Intravesical BCG Immunotherapy,” Clinical Infectious Diseases, Vol. 36, No. 2, 2003, pp. 140-148. doi:10.1086/344908